Princess Amalia Children's Clinic, Isala klinieken, PO Box 10400, 8000 GK Zwolle, the Netherlands.
Paediatr Respir Rev. 2011 Dec;12(4):245-9. doi: 10.1016/j.prrv.2011.05.009. Epub 2011 Sep 17.
Although montelukast is claimed to be preferable to inhaled corticosteroids in children with asthma and allergic rhinitis, virus-induced exacerbations, exercise induced asthma, and in those experiencing difficulties with inhalation therapy, there is no scientific evidence to support any of these claims. In comparative trials and systematic reviews, inhaled corticosteroids are clearly more effective than montelukast in reducing asthma exacerbations, improving lung function, symptom scores, and rescue medication use. The effects on exercise induced bronchoconstriction appear to be similar. Because of their superior efficacy and excellent long-term efficacy and safety profile, inhaled corticosteroids are the treatment of first choice for the maintenance therapy of childhood asthma, irrespective of age or clinical phenotype.
尽管有研究声称，在患有哮喘和变应性鼻炎的儿童中，孟鲁司特优于吸入性皮质类固醇，但该药对病毒诱发的加重、运动诱发的哮喘和吸入治疗有困难的患者，没有任何科学证据支持这些说法。在比较性试验和系统评价中，吸入性皮质类固醇在减少哮喘加重、改善肺功能、症状评分和急救药物使用方面明显优于孟鲁司特。对运动诱发性支气管收缩的影响似乎也相似。由于其疗效更好，长期疗效和安全性良好，吸入性皮质类固醇是儿童哮喘维持治疗的首选药物，无论年龄或临床表型如何。
